4-aminopyridine has been researched along with Abnormal Movements in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "2% of patients presented adverse drug reactions (ADRs) while using moderate doses of 3,4-DAP (20-30 mg daily or up to 80 mg daily for patients with LEMS) for periods of up to 51 months." | 2.75 | 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. ( Allain, H; Edan, G; Flet, L; Guillard, O; Javaudin, L; Leray, E; Polard, E, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flet, L | 1 |
| Polard, E | 1 |
| Guillard, O | 1 |
| Leray, E | 1 |
| Allain, H | 1 |
| Javaudin, L | 1 |
| Edan, G | 1 |
| Weisz, CJ | 1 |
| Raike, RS | 1 |
| Soria-Jasso, LE | 1 |
| Hess, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 4-aminopyridine and Abnormal Movements
| Article | Year |
|---|---|
3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Child; Cohort Studies; Dyskinesias; Fatigue | 2010 |
1 other study available for 4-aminopyridine and Abnormal Movements
| Article | Year |
|---|---|
Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering.
Topics: 4-Aminopyridine; Analysis of Variance; Animals; Behavior, Animal; Caffeine; Calcium Channels, N-Type | 2005 |